A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Shares of Moderna Inc. MRNA inched 0.02% higher to $41.84 Monday, on what proved to be an all-around mixed trading session ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Most years, I find one or two stocks among the biggest losers that I think are worth buying. This year there are three — ...

Steve Grasso, Grasso Global CEO, joins 'Power Lunch' to discuss stock plays for three stocks.

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Moderna contended in documents that it needs the larger, higher sign because it's blocked from anywhere other than right in front of the building by trees in the public park betwe ...

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.